C-028380 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 106 | クリオピリン関連周期熱症候群 | 1 |
106. クリオピリン関連周期熱症候群
臨床試験数 : 42 / 薬物数 : 24 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 48
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000489-40-GB (EUCTR) | 22/09/2020 | 03/04/2020 | A Phase IIb study to Evaluate the Safety, Tolerability and Efficacy of IZD174 in Patients with Cryopyrin-Associated Periodic Syndromes | A Multi-Centre, Randomised, Open-Label, Phase IIb Study to Evaluate the Safety, Tolerability and Efficacy of IZD174 in Patients with Cryopyrin Associated Periodic Syndromes | Cryopyrin-associated periodic syndrome (CAPS) MedDRA version: 20.0;Level: PT;Classification code 10068850;Term: Cryopyrin associated periodic syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: IZD174 Product Code: C-028380 INN or Proposed INN: N/A Other descriptive name: Inzomelid Product Name: IZD174 Product Code: C-028380 INN or Proposed INN: N/A Other descriptive name: Inzomelid | Inflazome (Australia) Pty Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 14 | Phase 2 | Ireland;Australia;United Kingdom |